document type sequence filename description text html head title title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align right confidential style margin margin bottom font size font family time roman align center amended restated style margin margin bottom font size font family time roman align center development license agreement style margin margin bottom font size font family time roman align center between style margin margin bottom font size font family time roman align center colucid pharmaceutical style margin margin bottom font size font family time roman align center style margin margin bottom font size font family time roman align center lilly company style margin margin bottom font size font family time roman align center effective february style page break before always size style color width align center style margin margin bottom font size font family time roman align center amended restated style margin margin bottom font size font family time roman align center development license agreement style margin margin bottom text indent font size font family time roman small small small mended small small small small estated small small evelopment small small small small icense small small greement small small small agreement entered into february nbsp restatement effective date between small small small ucid small small harmaceuticals small small small colucid corporation organized existing under state delaware having principal place business north capitol avenue suite indianapolis indiana small small small illy small small small small ompany small small small lilly corporation organized existing under state indiana having principal place business lilly corporate center indianapolis indiana colucid lilly sometimes referred herein individually party collectively party party agree follows style margin margin bottom font size font family time roman align center background style margin margin bottom text indent font size font family time roman lilly certain intellectual property right relating compound colucid interested further developing commercializing party entered into development license agreement dated december nbsp original agreement pursuant which lilly granted colucid license further develop commercialize worldwide basis pharmaceutical product containing style margin margin bottom text indent font size font family time roman original agreement amended certain matter confirmed pursuant nbsp letter dated december nbsp nbsp letter dated march nbsp nbsp letter dated june nbsp nbsp amendment dated nbsp nbsp letter dated january nbsp collectively prior amendment party desire further amend original agreement restate original agreement entirety forth this agreement after which this agreement shall represent complete understanding party with respect subject matter hereof supersedes replaces original agreement prior amendment style margin margin bottom text indent font size font family time roman small small small herefore small consideration above premise mutual covenant agreement forth below party hereto agree follows style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center definition style margin margin bottom text indent font size font family time roman used this agreement following word phrase shall have following meaning style margin margin bottom text indent font size font family time roman adverse event mean untoward medical occurrence patient clinical investigation subject administered medicinal product that have necessarily have have causal relationship with medicinal product including designated under other applicable style margin margin bottom text indent font size font family time roman affiliate mean with respect party person directly indirectly controlling controlled under common control with such party purpose this agreement term controlled including term controlled under common control with used this context mean direct indirect ability power direct cause direction management policy person otherwise direct affair such person whether through ownership equity voting security beneficial interest contract otherwise style margin margin bottom text indent font size font family time roman applicable mean applicable ordinance rule regulation kind whatsoever governmental including international foreign federal state local regulatory authority including without limitation ordinance rule regulation promulgated counterpart foreign jurisdiction style margin margin bottom text indent font size font family time roman application marketing authorization mean with respect product nbsp united state drug application filed with pursuant nbsp section nbsp section nbsp successor regulatory scheme nbsp country other than united state application application marketing approval comparable necessary make sell product commercially such country style margin margin bottom text indent font size font family time roman calendar quarter mean three nbsp month period ending march nbsp nbsp june nbsp nbsp september nbsp december nbsp initial calendar quarter will deemed begin original effective date expiration that calendar quarter which fall style margin margin bottom text indent font size font family time roman change control mean with regard party following event acquisition person other than person controlling such party original effective date beneficial ownership defined rule under united state security exchange amended directly indirectly more than fifty percent nbsp share such party stock merger sale stock excluding bona fide financing transaction sale other disposition substantially asset such party third person style margin margin bottom text indent font size font family time roman clinical trial mean phase clinical trial phase clinical trial phase clinical trial applicable style margin margin bottom text indent font size font family time roman closing date mean date closing next financing long such closing date occurs within sixty nbsp after original effective date such later date party agree style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman colucid technology mean invention idea conception font style white space nowrap reduction practice font patentable information work data that nbsp generated identified discovered created made whole part colucid affiliate employee third person behalf colucid nbsp controlled colucid affiliate nbsp necessary manufacture research develop sell seek regulatory approval including without limitation manufacturing process formulation mode delivery method toxicology study clinical trial information data post registration clinical trial information data each case relating compound product style margin margin bottom text indent font size font family time roman combination product mean product comprised combination product other product product component where nbsp manufacture importation sale other disposition other product product component itself behalf colucid another permitted seller constitute infringement valid claim nbsp other product product component sold separately colucid another permitted seller nbsp other product product component enhances market price product sold colucid another permitted seller style margin margin bottom text indent font size font family time roman compound mean trifluoro methyl piperidinyl carbonyl pyridyl benzamide which designated pharmaceutically acceptable salt solvate polymorph style margin margin bottom text indent font size font family time roman compound supply shall have meaning forth section style margin margin bottom text indent font size font family time roman confidential information mean information received whether disclosed writing electronically orally observation party receiving party from other party disclosing party that disclosing party reasonably considers proprietary confidential unless each case such information shown competent evidence style margin margin bottom text indent font size font family time roman known receiving party public prior disclosing party disclosure demonstrated contemporaneous written record style margin margin bottom text indent font size font family time roman became known public after disclosing party disclosure hereunder other than through breach confidentiality provision this agreement receiving party person whom such receiving party disclosed such information style margin margin bottom text indent font size font family time roman subsequently disclosed receiving party person having legal right disclose without restriction such information data style margin margin bottom text indent font size font family time roman developed receiving party independent disclosing party confidential information style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman provided however that licensed patent lilly know other information that pertains compound product disclosed colucid lilly hereunder shall deemed confidential information colucid well lilly subject confidentiality provision hereof during term this agreement style margin margin bottom text indent font size font family time roman control mean possession ability grant license without violating term agreement other arrangement with third person style margin margin bottom text indent font size font family time roman damage mean cost loss claim demand payment government enforcement action liability fine penalty expense court cost reasonable disbursement counsel consultant expert witness incurred party hereto affiliate including court imposed interest connection therewith style margin margin bottom text indent font size font family time roman data exclusivity period mean period during which country other than united state equivalent regulatory agency prohibits reference without consent owner application marketing authorization regulatory approval package clinical other data that contained such application marketing approval regulatory approval package that published publicly available outside such application marketing authorization regulatory approval package style margin margin bottom text indent font size font family time roman development plan mean plan prepared colucid developing product territory including filing application marketing authorization product including clinical trial required confirm profile product including limited clinical trial required confirm clinical efficacy tolerability dosing regimen product initial development plan attached exhibit provided however that colucid shall entitled amend alter change such development plan sole discretion subject obligation hereunder style margin margin bottom text indent font size font family time roman diligence mean reasonable commercial effort consistent with normal business practice within pharmaceutical industry taking into account efficacy competitiveness alternative product marketplace availability partner commercialization product degree intellectual property protection available product likelihood regulatory approval profitability product potential impact prevailing condition such pricing market more other market alternative product other relevant factor event than effort comparable with those used colucid similar product comparable stage development comparable commercial development potential light such factor with objective launching product worldwide soon practicable style margin margin bottom text indent font size font family time roman mean united state food drug administration successor federal agency having responsibility over regulatory approval shall also deemed include applicable governmental regulatory authority having jurisdiction over product particular country region territory example european medicine evaluation agency european union style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman field mean human health style margin margin bottom text indent font size font family time roman first commercial sale mean first length sale product country colucid permitted seller third person following regulatory approval that country style margin margin bottom text indent font size font family time roman force majeure shall have meaning forth section style margin margin bottom text indent font size font family time roman gaap mean generally accepted accounting principle consistently applied style margin margin bottom text indent font size font family time roman licensed patent mean those united state foreign patent patent application including provisional application listed exhibit extent they cover making using selling compound including without limitation style margin margin bottom margin left text indent font size font family time roman division continuation these application patent issuing from such application division continuation reissue reexamination extension such patent style margin margin bottom margin left text indent font size font family time roman continuation part division continuation these continuation part patent issuing from such continuation part division continuation reissue reexamination extension such patent each case extent that they contain more claim directed invention invention disclosed patent application listed exhibit style margin margin bottom text indent font size font family time roman lilly know mean know trade secret invention technology information data idea specification formula formulation procedure process plan design instruction study method similar item related documentation record material relating compound including information relating previous generation compound known only extent relevant development compound that owned controlled lilly original effective date necessary relevant manufacture research develop sell seek regulatory approval product including preclinical clinical development data information biological chemical pharmacological toxicological pharmaceutical data information manufacturing method manufacturing quality control data information formulation analysis market research specific product similar item lilly know include licensed patent style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman major market mean japan france germany italy spain united kingdom united state style margin margin bottom text indent font size font family time roman meaning forth under definition application marketing authorization style margin margin bottom text indent font size font family time roman sale mean gross amount invoiced sale product permitted seller following item consistent with gaap style margin margin bottom margin left text indent font size font family time roman trade quantity cash discount actually allowed style margin margin bottom margin left text indent font size font family time roman commission discount refund rebate charge back retroactive price adjustment other allowance paid third party that effectively reduce selling price style margin margin bottom margin left text indent font size font family time roman actual product return allowance style margin margin bottom margin left text indent font size font family time roman duty imposed production sale delivery product including limited sale excise value added other than income style margin margin bottom margin left text indent font size font family time roman other expense directly related sale product that allowed gaap provided that such expense reasonable taken good faith style margin margin bottom text indent font size font family time roman product which sold combination product sale such combination product shall adjusted multiplying actual sale fraction where invoice price product sold separately nbsp invoice price other product product component sold separately other product product component sold separately then actual sale shall adjusted multiplying actual sale fraction where invoice price product sold separately invoice price combination product neither foregoing applies then party shall determine sale combination product good faith style margin margin bottom text indent font size font family time roman sale amount shall determined from book record permitted seller maintained accordance with gaap consistently applied further determining such amount colucid will colucid then current standard procedure methodology including colucid then current standard exchange rate methodology translation foreign currency sale into dollar case other permitted seller such similar methodology consistently applied style margin margin bottom text indent font size font family time roman next financing mean colucid next sale preferred stock after original effective date with aggregate proceeds colucid equal exceeding style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman including proceeds attributable conversion unpaid principal amount unpaid accrued interest outstanding convertible promissory note issued colucid venture capital institutional private investor single transaction series related transaction style margin margin bottom text indent font size font family time roman original agreement meaning forth first paragraph under background above style margin margin bottom text indent font size font family time roman original effective date mean december nbsp style margin margin bottom text indent font size font family time roman permitted seller mean colucid affiliate permitted assignee licensee sublicensee having right sell product hereunder style margin margin bottom text indent font size font family time roman person mean natural person corporation partnership trust joint venture limited liability company governmental authority other entity organization style margin margin bottom text indent font size font family time roman phase clinical trial mean human clinical trial conducted establish initial safety profile pharmacodynamics product particular indication tested style margin margin bottom text indent font size font family time roman phase clinical trial mean human clinical trial conducted achieve level efficacy safety product well preliminary dosage particular indication tested style margin margin bottom text indent font size font family time roman phase clinical trial mean human clinical trial conducted establish efficacy product meet requirement file application marketing authorization product with health regulatory authority particular indication tested style margin margin bottom text indent font size font family time roman prior amendment meaning forth second paragraph under background above style margin margin bottom text indent font size font family time roman product mean final form human pharmaceutical composition preparation dosage strength size mode administration containing compound subject foregoing product shall deemed include expansion improvement modification thereon made behalf colucid affiliate otherwise owned controlled colucid affiliate style margin margin bottom text indent font size font family time roman regulatory approval mean approval application marketing authorization satisfaction related applicable registration notification requirement style margin margin bottom text indent font size font family time roman regulatory document shall have meaning forth section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman restatement effective date shall have meaning forth first paragraph hereof style margin margin bottom text indent font size font family time roman royalty term mean with respect each country which product sold product product basis that time period beginning first commercial sale product such country expiring country country basis following date style margin margin bottom margin left text indent font size font family time roman later tenth anniversary date first commercial sale product such country expiration such country last expire licensed patent with valid claim style margin margin bottom margin left text indent font size font family time roman there data exclusivity period effect such country product after expiration applicable time period nbsp which provides effective market exclusivity product above expiration such data exclusivity period such country style margin margin bottom text indent font size font family time roman territory mean country world style margin margin bottom text indent font size font family time roman third person mean person other than party affiliate thereof style margin margin bottom text indent font size font family time roman valid claim mean claim issued unexpired patent included within licensed patent country which nbsp this agreement would infringed manufacture importation sale other disposition product behalf colucid another permitted seller nbsp been revoked held unenforceable invalid decision court other governmental agency competent jurisdiction unappealable unappealed within time allowed appeal nbsp been abandoned disclaimed admitted invalid unenforceable through reissue disclaimer otherwise style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center grant license style margin margin bottom text indent font size font family time roman license subject term condition forth herein during term this agreement lilly grant colucid exclusive except lilly internal research purpose forth section nbsp below license with right sublicense accordance with section nbsp under lilly know licensed patent make have made sell offer sale import compound product field territory which license shall effective closing date style margin margin bottom text indent font size font family time roman reservation right notwithstanding license granted colucid under section nbsp lilly reserve right under license conduct research compound product internal research purpose only style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman intentionally omitted style margin margin bottom text indent font size font family time roman sublicensing right colucid sublicenses colucid sublicense right granted hereunder affiliate third person provided however that colucid shall notify lilly thirty nbsp advance granting sublicense will discus good faith concern lilly have with such sublicense colucid will remain liable royalty payment result sale made permitted seller pursuant sublicense milestone other payment permitted pursuant this section nbsp each sublicense granted colucid under this agreement will contain provision that obligate sublicensees colucid least same extent that colucid obligated lilly under this agreement additionally promptly after execution colucid shall provide lilly with copy sublicense agreement style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center consideration style margin margin bottom text indent font size font family time roman payment from colucid lilly style margin margin bottom margin left text indent font size font family time roman issuance common stock closing date subject term condition hereof colucid shall issue lilly number share initial share colucid common stock common stock such that immediately after initial closing next financing lilly will post financing share common stock hereinafter defined outstanding immediately after initial closing next financing event investor next financing purchase additional share colucid preferred stock pursuant transaction agreement entered into next financing subsequent closing each subsequent closing colucid shall issue lilly such additional share common stock supplemental share together with initial share share immediately after subsequent closing such that lilly will post financing share common stock outstanding immediately after each subsequent closing next financing post financing share common stock mean share colucid common stock assuming conversion outstanding share colucid preferred stock into common stock then applicable conversion rate nbsp issued prior date hereof plus nbsp issued issuable sention sention connection with next financing provided asset purchase agreement dated date hereof between colucid sention applicable closing date next financing plus nbsp issued next financing maximum aggregate next financing amount million plus nbsp issued reserved issuance pursuant exercise stock option which have granted under colucid stock option plan closing date plus nbsp issued issuable lilly pursuant this agreement applicable closing date next financing style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left text indent font size font family time roman colucid payment upon closing date closing date colucid will lilly creditable refundable nbsp million dollar federal reserve electronic wire transfer immediately available fund account designated lilly style margin margin bottom margin left text indent font size font family time roman milestone payment from colucid lilly within thirty nbsp colucid permitted seller achieving milestone event listed below with respect product colucid will notify lilly writing thereof below specified creditable refundable lilly federal reserve electronic wire transfer immediately available fund account designated lilly style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign bottom align center milestone event valign bottom nbsp nbsp valign bottom align center payment style font size height height colspan style font family time roman font size valign filing first valign bottom nbsp nbsp valign three million dollar style font size height height colspan style font family time roman font size valign filing first major market valign bottom nbsp nbsp valign million five hundred thousand dollar style font size height height colspan style font family time roman font size valign filing first japan valign bottom nbsp nbsp valign million five hundred thousand dollar style font size height height colspan style font family time roman font size valign first regulatory approval valign bottom nbsp nbsp valign eleven million dollar style font size height height colspan style font family time roman font size valign first regulatory approval major market valign bottom nbsp nbsp valign million five hundred thousand dollar style font size height height colspan style font family time roman font size valign first regulatory approval japan valign bottom nbsp nbsp valign million five hundred thousand dollar style font size height height colspan style font family time roman font size valign first fiscal year colucid which aggregate sale exceed valign bottom nbsp nbsp valign million dollar style font size height height colspan style font family time roman font size valign approval each subsequent indication paid more than time compound valign bottom nbsp nbsp valign million dollar indication market major market japan table style margin margin bottom text indent font size font family time roman avoidance doubt colucid shall required milestone more than time compound except stated above style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman milestone event achieved with respect compound such time more milestone event previously listed country which milestone achieved been achieved with respect compound then time payment milestone payment such achieved milestone event colucid shall lilly previously listed unpaid payment such unmet milestone event including filing equivalent major market japan subsequent milestone event payment will paid within thirty nbsp colucid lilly such milestone event achieved style margin margin bottom margin left text indent font size font family time roman royalty payment from colucid lilly colucid shall lilly royalty sale product permitted seller during royalty term follows style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style margin margin bottom font size font family time roman sale each fiscal style margin margin bottom border bottom solid width font size font family time roman year colucid valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid royalty nbsp rate valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp table style margin margin bottom text indent font size font family time roman beginning with year which submission occurs such year being base year from which future adjustment will made sale tier specified above shall adjusted each january nbsp accordance with bureau labor statistic united state consumer price index then just ended calendar year style margin margin bottom text indent font size font family time roman country person other than colucid affiliate sublicensees introduces final form human pharmaceutical composition preparation dosage strength size mode administration containing generic equivalent compound applicable which generic equivalent received authorization approval required applicable such sale sale such generic equivalent represent least total sale such country unit basis then royalty rate payable colucid with respect sale that product such country shall reduced style margin margin bottom text indent font size font family time roman style margin margin bottom text indent font size font family time roman event practice licensed patent consistent with term this agreement result nbsp infringement claim third party nbsp desire part colucid enter into third party license agreement based good faith opinion that infringement against such third party patent occur without such license notice concurrence lilly such third party license which concurrence shall unreasonably withheld colucid shall entitled credit against royalty otherwise owed lilly under section nbsp above amount actually paid colucid such third party license under patent owned controlled such third party provided however that colucid only credit against royalty otherwise style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman calendar year such amount that nbsp directly attributable manufacture sale product with respect other product nbsp that total such calendar year exceed sale except forth this paragraph colucid shall solely responsible royalty other payment third party product style margin margin bottom text indent font size font family time roman lilly acknowledges that colucid seek enter into licensing commercialization sublicensing transaction described section nbsp other collaboration arrangement event that colucid seek enter such collaboration arrangement determines good faith that able term that reasonably satisfactory colucid based part amount royalty rate forth section nbsp related term this agreement then colucid give notice such determination lilly style margin margin bottom text indent font size font family time roman colucid shall royalty under this section nbsp concurrently with remittance royalty report accordance with section nbsp amount payable lilly under section nbsp shall paid dollar federal reserve electronic wire transfer immediately available fund account designated writing lilly unless otherwise instructed lilly writing style margin margin bottom text indent font size font family time roman record retention royalty report royalty payment schedule colucid shall keep shall cause affiliate require sublicensees keep complete accurate book record that necessary ascertain colucid compliance with this agreement including such record necessary verify royalty payment owed under section nbsp such record shall kept accordance with gaap colucid sublicensees internal practice procedure consistently applied beginning with first commercial sale product colucid shall furnish lilly with quarterly report sale product within sixty nbsp after each calendar quarter such report shall include written report detailing nbsp sale product previous calendar quarter broken down country between colucid permitted seller nbsp royalty payment that payable nbsp basis calculating such royalty payment colucid will mail such report attention lilly company lilly royalty administration finance drop code lilly corporate center indianapolis indiana unless otherwise instructed lilly writing amount royalty payment lilly shall paid colucid concurrently with remittance each royalty report that within sixty nbsp each calendar quarter style margin margin bottom text indent font size font family time roman milestone payment creditable colucid milestone payment under this article creditable against colucid royalty obligation lilly under this article style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman audit lilly will have right during regular business hour upon reasonable advance notice have such book record colucid described section nbsp audited more than nbsp time calendar year verify colucid compliance with term this agreement such audit cover nbsp calendar year preceding date request such audit cover other calendar year provided however that lilly audit given calendar year only once such audit right shall continue nbsp calendar year following termination agreement style margin margin bottom text indent font size font family time roman lilly will keep confidential information obtained during such audit cost such audit will borne lilly however result such audit party agree that amount royalty owed lilly greater than equal five percent nbsp more than amount royalty paid calendar year that subject audit reasonable cost audit will borne colucid within thirty nbsp after both party have received copy audit report colucid lilly appropriate will compensate other party payment error omission revealed audit colucid will include sublicenses granted accordance herewith other agreement enabling third person permitted seller audit provision substantially similar foregoing requiring such permitted seller keep full accurate book record relating product granting lilly right audit accuracy information reported sublicensee connection therewith style margin margin bottom text indent font size font family time roman currency payment made under this agreement shall united state dollar levied royalty milestone payment made colucid lilly under this agreement shall liability paid lilly colucid shall responsible other regulation require withholding such will deducted colucid from payment remitted colucid proper authority provided that colucid will furnish lilly with copy official receipt such withholding soon practicable after such withholding give lilly such assistance lilly expense reasonably necessary enable assist lilly claim exemption take credit therefrom proof payment shall provided lilly within sixty nbsp after payment colucid will cooperate lilly expense pursuing refund such refund appropriate lilly determination style margin margin bottom text indent font size font family time roman late payment amount paid colucid when under this agreement will subject interest from including date payment through including date upon which lilly collected fund accordance herewith rate equal lesser nbsp five percent nbsp plus prime rate interest quoted money rate equivalent section wall street journal annum calculated daily basis three hundred sixty nbsp year nbsp maximum interest rate allowed style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center initiation conduct development style margin margin bottom font size font family time roman align center commercialization product style margin margin bottom text indent font size font family time roman colucid lilly representative promptly later than thirty nbsp after closing date colucid shall designate writing colucid representative that shall have responsibility communicating with lilly personnel regarding transition support development commercialization product under this agreement including provision that individual name title phone number colucid change such representative from time time written notice lilly containing name contact information representative likewise lilly will promptly later than thirty nbsp after closing date designate writing lilly representative that shall have responsibility communicating with colucid under this agreement including provision that individual name title phone number lilly change such representative from time time written notice colucid containing name contact information representative style margin margin bottom text indent font size font family time roman transfer patent file lilly know transition support style margin margin bottom margin left text indent font size font family time roman transfer patent file lilly shall deliver instruct lilly counsel deliver colucid copy original file lilly lilly counsel relating licensed patent being understood that lilly promptly shall initiate delivery process that such copy shall delivered colucid within thirty nbsp after closing date lilly also shall promptly forward instruct lilly counsel forward colucid correspondence other communication relating licensed patent that lilly counsel employed lilly receive from patent office connection with licensed patent style margin margin bottom margin left text indent font size font family time roman provision lilly know within ninety nbsp closing date lilly shall commercially reasonable effort supply colucid with lilly know identified exhibit style margin margin bottom margin left text indent font size font family time roman transition support party agree work good faith complete provision lilly know identified exhibit colucid within ninety nbsp closing date transition period addition during this time lilly will grant colucid access during normal business hour appropriate lilly personnel reasonable consultation related lilly know except forth section nbsp below such access lilly personnel during transition period cost colucid shall exceed total hundred nbsp lilly person hour lilly shall have obligation provide support type beyond hour mentioned above after transition period however lilly agrees provide additional support colucid shall promptly lilly nbsp amount equal hundred style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman seventy five dollar hour each such hour service provided lilly nbsp expense forth section nbsp lilly belief that information listed exhibit represents document lilly know that lilly possession that would useful relevant colucid colucid significant need access lilly document lilly know listed exhibit request that lilly provide such information which case lilly will reasonable effort locate provide such information colucid expense understood that such request should infrequent unusual nature that reasonable effort should taken avoid additional substantial burden lilly colucid advised lilly that colucid desire retain service nbsp nabih ramadan served consultant lilly lilly objection nbsp ramadan providing such service lilly agrees confirm this writing nbsp ramadan promptly upon request nbsp ramadan colucid style margin margin bottom margin left text indent font size font family time roman payment expense colucid will reimburse lilly within thirty nbsp receipt lilly invoice together with proper supporting documentation reasonable actual travel associated accommodation meal expense lilly personnel travel upon colucid request connection with provision transition support style margin margin bottom text indent font size font family time roman colucid obligation develop compound product colucid shall diligence develop product obtain regulatory approval major market colucid shall responsible financially otherwise further development clinical clinical product lilly shall have obligation with respect thereto colucid sublicensees shall have responsibility seeking necessary regulatory approval develop product colucid sublicensees shall hold legal title application marketing authorization within territory shall assume full responsibility clinical protocol developed support such application marketing authorization lilly shall have financial obligation relating compound product colucid itself through sublicensees shall diligence researching developing product otherwise carrying duty contemplated under this agreement colucid will responsible regulatory requirement during development commercialization compound product style margin margin bottom text indent font size font family time roman colucid obligation update lilly product development progress least once every year colucid representative shall provide lilly representative with copy then current development plan summary activity conducted during preceding year addition least once year colucid shall provide copy detailed year written report describing progress made implementing development plan each such report shall include with respect applicable nbsp year period description research development activity conducted both united state outside united style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman state with respect product well amendment revision development plan colucid shall provide lilly with regular telephonic update progress made implementing development plan other information lilly reasonably request style margin margin bottom text indent font size font family time roman colucid commercialization obligation style margin margin bottom margin left text indent font size font family time roman product receives regulatory approval given country colucid shall diligence commercialize product such country style margin margin bottom margin left text indent font size font family time roman colucid obligation notify lilly right terminate failure colucid market product colucid shall promptly notify lilly colucid decides style margin margin bottom margin left text indent font size font family time roman file regulatory approval market product major market style margin margin bottom margin left text indent font size font family time roman discontinue reason other than force majeure marketing product major market style margin margin bottom margin left text indent font size font family time roman resume marketing product major market following expiration force majeure event style margin margin bottom text indent font size font family time roman such notice failure file market case shall deemed material breach under section nbsp style margin margin bottom text indent font size font family time roman adverse event reporting colucid agrees report adverse event that occur during development marketing product relevant regulatory authority promptly according applicable colucid will responsible safety pharmacovigilance activity under applicable after closing date style margin margin bottom text indent font size font family time roman governmental filing lilly colucid each agree prepare file whatever filing request application required filed with governmental authority connection with transfer right article this agreement cooperate with another reasonably necessary accomplish foregoing style margin margin bottom text indent font size font family time roman compliance with colucid will comply material respect with applicable relating development manufacture distributing marketing promotion selling importing exporting product colucid agrees acknowledges that holder regulatory document with respect product will have sole responsibility among other thing adverse event reporting other regulatory reporting regulatory document maintenance obligation style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center supply compound style margin margin bottom text indent font size font family time roman transfer compound supply lilly hereby assigns transfer conveys colucid effective closing date lilly right title interest lilly supply compound compound intermediate described exhibit compound supply within ninety nbsp business closing date such other delivery schedule reasonably acceptable each party lilly will transfer colucid compound supply well existing documentation method standard related compound supply compound supply being transferred without warranty that compound supply suitable human testing once possession compound supply transferred colucid colucid shall responsible performing having third person perform quality control quality assurance analytical assay including developmental release related substance stability toxicology dosage form study assay addition colucid shall comply with restriction compound supply forth exhibit style margin margin bottom text indent font size font family time roman additional supply compound except forth section nbsp colucid shall expense provide quantity compound compound intermediate product that colucid need accommodate development commercialization effort under this agreement colucid acknowledges that lilly will supply quantity compound compound intermediate other than that forth exhibit style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center intellectual property style margin margin bottom text indent font size font family time roman intellectual property maintenance licensed patent shall filed prosecuted maintained worldwide third person patent counsel designated colucid reasonably acceptable lilly colucid shall have ultimate responsibility control over such matter shall bear expense incurred filing prosecuting maintaining licensed patent colucid designee shall keep lilly informed filing prosecution maintenance licensed patent shall furnish lilly copy substantive document office action response relevant such effort advance with sufficient time lilly review provide comment such document shall good faith take such comment into account colucid decides allow licensed patent lapse colucid wish abandon licensed patent colucid shall notify lilly writing than sixty nbsp prior taking such action lilly shall have right assume responsibility such licensed patent lilly then colucid shall style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman surrender lilly right under article under patent patent application country country affected lilly assume control same lilly sole expense being understood that other right under license such licensed patent other country other licensed patent under article continue style margin margin bottom text indent font size font family time roman enforcement intellectual property right colucid lilly will promptly notify other infringement misappropriation suspected infringement misappropriation that come notice intellectual property right relating product including without limitation licensed patent lilly know will provide other party with information with respect thereto third person infringes licensed patent lilly know colucid will have first right obligation expense pursue injunctive relief compensatory other remedy relief collectively remedy against such third person lilly will have right participate such action expense should colucid determine pursue remedy with respect such infringement misappropriation licensed patent lilly know within sixty nbsp after receipt written notice from lilly requesting colucid then lilly will have right obligation expense pursue remedy against such third person colucid shall have right participate such action expense style margin margin bottom text indent font size font family time roman assistance cooperation party pursues remedy hereunder with respect infringement misappropriation colucid technology licensed patent lilly know other party will reasonable effort assist cooperate with party pursuing such remedy including joining action providing power attorney necessary each party will bear cost expense relating such pursuit damage other amount collected will distributed first party that pursued remedy cover cost expense second other party cover cost expense relating pursuit such remedy remaining amount will distributed party that pursued remedy provided that recovery colucid attributable lost sale shall deemed sale hereunder royalty paid thereon style margin margin bottom text indent font size font family time roman settlement litigation settlement consent judgment other final disposition action infringement validity entered into party licensed patent lilly know without other party prior written consent which consent shall unreasonably withheld style margin margin bottom text indent font size font family time roman infringement third person right third person institute patent trade secret other infringement suit against colucid permitted seller during term this agreement alleging that manufacture marketing sale importation product infringes more patent other intellectual property right held such third person then colucid will have sole right style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman obligation sole expense assume direction control defense such claim colucid request lilly will provide reasonable assistance connection with defense such claim colucid will reimburse lilly documented reasonable expense incurred lilly connection therewith colucid will have right settle otherwise dispose such claim without consent lilly which consent will unreasonably withheld unless there finding admission either infringement validity licensed patent lilly know style margin margin bottom text indent font size font family time roman colucid technology colucid will sole owner colucid technology colucid shall bear expense incurred preparing filing prosecuting maintaining patent application patent that encompass colucid technology colucid designee shall keep lilly reasonably informed filing prosecution maintenance patent patent application encompassing colucid technology style margin margin bottom text indent font size font family time roman failure maintain application patent colucid decides maintain continue prosecute patent application patent encompassing colucid technology shall give lilly reasonable written notice this effect after such notice lilly expense maintain continue prosecute such application patent colucid shall assign such application patent lilly style margin margin bottom text indent font size font family time roman patent reporting within sixty nbsp after each calendar year colucid shall provide lilly with written report describing status licensed patent including patent country patent application number filing date issue date expiration date other relevant information requested lilly such report shall mailed lilly company lilly royalty administration finance drop code lilly corporate center indianapolis indiana unless lilly advises otherwise writing with copy general patent counsel style margin margin bottom text indent font size font family time roman trademark colucid will responsible trademark related marketing product will responsible sole discretion registering defending maintaining such trademark style margin margin bottom text indent font size font family time roman patent cooperation each party hereby agrees make employee agent consultant reasonably available other party other party authorized attorney agent representative other party expense extent reasonably necessary enable party responsible prosecuting licensed patent undertake preparation filing prosecution maintenance licensed patent style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman patent term extension certification style margin margin bottom margin left text indent font size font family time roman requested colucid lilly shall cooperate obtaining patent term restoration supplementary protection certificate their equivalent patent term extension including limited those available under hatch waxman licensed patent covering claiming product country region where applicable lilly shall provide reasonable assistance requested colucid including permitting colucid proceed with application such name lilly reasonably deemed appropriate colucid executing document authorization required providing relevant information colucid style margin margin bottom margin left text indent font size font family time roman colucid shall sole discretion determine which licensed patent will apply extend style margin margin bottom margin left text indent font size font family time roman requested colucid lilly shall cooperate maintaining with applicable government regulatory authority during term correct complete listing applicable licensed patent product being commercialized including orange book listing required under font style white space nowrap hatch waxman font style margin margin bottom margin left text indent font size font family time roman colucid shall responsible pocket expense incurred lilly providing foregoing cooperation assistance pursuant paragraph style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center confidentiality style margin margin bottom text indent font size font family time roman confidential information party agree that unless receiving party obtains prior written consent disclosing party time during term this agreement year period following expiration earlier termination receiving party will keep completely confidential will publish otherwise disclose will directly indirectly purpose other than contemplated this agreement confidential information disclosing party whether such confidential information received receiving party prior after original effective date confidential information exchanged under confidentiality agreement dated september nbsp shall also included this section nbsp style margin margin bottom text indent font size font family time roman limited disclosure permitted each party disclose confidential information extent that such disclosure style margin margin bottom margin left text indent font size font family time roman required opinion legal counsel receiving party provided however that receiving party will first have given reasonable notice disclosing party practicable given disclosing party reasonable opportunity obtain protective order confidential treatment requiring that confidential information document that subject thereof held confidence recipient disclosed used only purpose required such provided further however that protective order obtained confidential information disclosed will limited that information that legally required disclosed required applicable style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left text indent font size font family time roman made receiving party governmental regulatory authority including required conduct clinical trial obtain maintain marketing approval product provided that reasonable effort will taken ensure confidential treatment such information style margin margin bottom margin left text indent font size font family time roman made receiving party third person necessary useful connection with manufacture development commercialization product provided that receiving party will each case obtain from proposed third person recipient written confidentiality agreement containing confidentiality obligation protective than those forth this agreement style margin margin bottom margin left text indent font size font family time roman made receiving party united state foreign authority style margin margin bottom margin left text indent font size font family time roman made receiving party representative third person connection with financing partnering sublicensing activity potential change control transaction involving receiving party provided however that nbsp each such representative third person need know such confidential information obligation maintain confidentiality such information nbsp receiving party informs each representative third person receiving confidential information confidential nature nbsp receiving party will responsible breach this article representative such third person same extent breach were receiving party style margin margin bottom margin left text indent font size font family time roman made receiving party representative receiving party filing publication patent patent application relating licensed patent lilly know colucid technology invention relating compound product extent such disclosure filing publication patent patent application reasonably necessary support patent patent application style margin margin bottom margin left text indent font size font family time roman made lilly attorney accountant consultant other professional extent necessary obtain their service connection with monitoring lilly investment colucid style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left text indent font size font family time roman made lilly affiliate lilly ordinary course business provided that lilly remains responsible breach affiliate this section nbsp style margin margin bottom margin left text indent font size font family time roman made receiving party order comply with applicable security disclosure requirement disclosure requirement applicable stock market security exchange style margin margin bottom text indent font size font family time roman disclosure agreement except contemplated herein neither party shall disclose this agreement redacted version thereof third person without prior written consent other party without limitation these prohibition apply press release annual report prospectus public statement educational scientific conference promotional material governmental filing discussion with public official security analyst medium however subject requirement review approval that follow this provision apply disclosure regarding this agreement which counsel party advised required applicable regulatory agency such security exchange commission federal trade commission department justice applicable stock market security exchange this includes request copy this agreement related information authority notwithstanding foregoing receiving party disclose term contained this agreement third person connection with activity transaction involving receiving party forth section nbsp press release announcing signing this agreement shall mutually approved party style margin margin bottom text indent font size font family time roman party this agreement determines release information regarding existence term this agreement required applicable prior release such information that party will notify other party writing soon practical provide much detail possible relation disclosure required where possible under applicable will endeavor good faith provide other party with minimum five nbsp business review proposed public statement party will then discus what information will actually released that party shall obtain other party prior written consent conduct action reasonably take prevent limit requested disclosure addition lilly shall have right review comment redaction this agreement required other agency colucid shall good faith taking lilly comment into account prior releasing redaction such agency style margin margin bottom text indent font size font family time roman survival confidentiality obligation this article shall survive termination expiration this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center representation warranty covenant disclaimer style margin margin bottom text indent font size font family time roman litigation infringement each party represents that best knowledge original effective date there litigation proceeding pending threatened against involving such party court before agency regulatory body which could adversely affect such party ability right carry transaction contemplated this agreement lilly represents warrant that there pending litigation proceeding which alleges that activity relating licensed patent lilly know compound have violated intellectual property right other person received written communication threatening such litigation proceeding style margin margin bottom text indent font size font family time roman debarment each party represents warrant other that will comply time with provision generic drug enforcement upon request each party will certify writing other party that neither such party employee person providing service such party under this agreement been debarred under provision such style margin margin bottom text indent font size font family time roman corporate existence original effective date each party represents warrant other that company duly organized validly existing relevant jurisdiction formation good standing under jurisdiction which formed style margin margin bottom text indent font size font family time roman authority execute perform original effective date each party represents warrant other that style margin margin bottom margin left text indent font size font family time roman power authority legal right enter into this agreement perform obligation hereunder style margin margin bottom margin left text indent font size font family time roman taken necessary company action part required authorize execution delivery this agreement style margin margin bottom margin left text indent font size font family time roman duly executed delivered agreement which constitutes legal valid binding obligation which enforceable against accordance with agreement term style margin margin bottom text indent font size font family time roman additional lilly representation warranty covenant style margin margin bottom text indent font size font family time roman development activity restatement effective date lilly represents warrant colucid that presently developing participating development present plan develop participate development style font size vertical align bottom selective compound defined below addition lilly agrees that will undertake human clinical testing with respect font style white space nowrap font style font size vertical align bottom selective compound treatment prevention migraine headache pain grant such right third person period five nbsp year from restatement effective date long this agreement full force effect style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman notwithstanding foregoing this provision shall apply nbsp event merger acquisition involving lilly another company where such company engaged such research nbsp style font size vertical align bottom selective compound with respect which lilly acquired right licensing transaction otherwise after restatement effective date used herein style font size vertical align bottom selective compound shall mean compound that functionally agonistic activity style font size vertical align bottom receptor site such activity principal clinically desirable pharmacological activity avoidance doubt compound included within definition style font size vertical align bottom selective compound understood that subject section nbsp lilly nbsp time future have pursue development effort indication with respect compound that principally target other receptor nbsp following five year period referenced above pursue development including human testing style font size vertical align bottom selective compound other than compound indication style margin margin bottom text indent font size font family time roman patent lilly represents warrant colucid original effective date that lilly owns licensed patent nothing this agreement shall constitute representation warranty lilly that licensed patent will valid that exercise licensed patent will infringe intellectual property right others event lilly subsequently discovers that control original effective date other patent right other than licensed patent that necessary exercise licensed patent then lilly will without further consideration amend this agreement include such patent right within scope licensed patent style margin margin bottom text indent font size font family time roman purchase entirely account this agreement made with lilly reliance upon lilly representation colucid which lilly execution this agreement lilly hereby confirms that share purchased lilly will acquired investment lilly account nominee agent with view resale distribution part thereof that lilly present intention selling granting participation otherwise distributing same executing this agreement lilly further represents that lilly have contract undertaking agreement arrangement with person sell transfer grant participation such person third person with respect share style margin margin bottom text indent font size font family time roman reliance upon lilly representation lilly understands that share registered under security amended security ground that sale provided this agreement issuance share hereunder exempt from registration under security pursuant section nbsp thereof that colucid reliance such exemption predicated lilly representation forth herein lilly realizes that basis exemption present notwithstanding such representation lilly mind merely acquiring share fixed determinable period future market rise sale market rise lilly such intention style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman receipt information lilly represents that lilly opportunity question receive answer from colucid regarding term condition offering share business property financial condition colucid obtain additional information necessary verify accuracy information furnished lilly which lilly access foregoing however limit modify representation warranty colucid this article right lilly rely thereon style margin margin bottom text indent font size font family time roman investment experience lilly represents that lilly experienced evaluating investing private placement transaction security company similar stage development acknowledges that lilly able fend itself bear economic risk lilly investment such knowledge experience financial business matter that lilly capable evaluating merit risk investment share style margin margin bottom text indent font size font family time roman accredited investor lilly represents colucid that lilly accredited investor within meaning rule regulation adopted pursuant security style margin margin bottom text indent font size font family time roman restricted security lilly understands that share sold transferred otherwise disposed without registration under security exemption therefrom that absence effective registration statement covering share available exemption from registration under security share must held indefinitely particular lilly aware that share sold pursuant rule promulgated under security unless condition that rule among condition rule nbsp availability current information public about colucid such information available style margin margin bottom text indent font size font family time roman legend extent applicable each certificate other document evidencing share shall endorsed with legend substantially form forth below style margin margin bottom text indent font size font family time roman following legend under security style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman share represented hereby have been registered under security amended sold transferred assigned pledged hypothecated unless until registered under such unless company received opinion counsel other evidence satisfactory company counsel that such registration required style margin margin bottom text indent font size font family time roman legend imposed required colucid bylaw applicable state security agreement referred section style margin margin bottom text indent font size font family time roman between original effective date closing date lilly shall commercially reasonable effort preserve maintain lilly know licensed patent compound shall enter into agreement arrangement with third person which conflict inconsistent with this agreement style margin margin bottom text indent font size font family time roman additional colucid representation warranty covenant style margin margin bottom text indent font size font family time roman valid issuance share share that being purchased lilly hereunder when issued sold delivered accordance with term this agreement consideration expressed herein will duly validly issued fully paid nonassessable will free restriction transfer other than restriction transfer under this agreement under applicable federal state security style margin margin bottom text indent font size font family time roman private offering subject part truth accuracy lilly representation forth this agreement offering sale issuance share contemplated this agreement exempt from registration requirement security applicable state security neither colucid authorized agent acting behalf will take action hereafter that would cause loss such exemption style margin margin bottom text indent font size font family time roman disclaimer implied warranty except expressly provided this section lilly make representation warranty licensed patent lilly know compound compound supply product express implied either fact operation statute otherwise lilly specifically disclaims implied statutory warranty including warranty merchantability infringement fitness particular purpose further except expressly forth this agreement neither party make representation style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman warranty under this agreement express implied either fact operation statute otherwise each party specifically disclaims implied statutory warranty including warranty merchantability fitness particular purpose without limiting foregoing colucid acknowledges that relying upon implied warranty merchantability fitness particular purpose otherwise upon representation warranty whatsoever prospect financial regulatory otherwise validity likelihood success compound product after original effective date style margin margin bottom text indent font size font family time roman disclaimer incidental consequential damage neither party will liable other party indirect incidental consequential special damage lost profit arising from relating breach this agreement regardless notice possibility such damage nothing this section intended limit restrict indemnification right obligation party style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center registration information right style margin margin bottom text indent font size font family time roman piggy back registration colucid intends register security public offering security solely cash other than certain registration relating sale security employee rule transaction registration form that include substantially same information would required included registration statement covering sale share colucid will give lilly notice such registration upon prompt request lilly colucid will cause registered share that lilly requested included such registration registration involves underwriting lilly will enter into underwriting agreement with underwriter containing customary provision including indemnification underwriter determines that number share underwritten registration must limited underwriter colucid limit some share included such registration lilly agrees that registration right described above subordinate registration right granted next financing that colucid grant time registration right which senior with junior lilly right lilly will furnish such information reasonably requested connection with registration will enter into customary indemnification agreement with colucid further lilly will bear expense counsel other customary selling expense provision this section nbsp shall survive expiration termination this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman information right colucid will provide lilly within after each fiscal year audited financial statement consisting balance sheet such year statement income cash flow such year statement stockholder equity such year colucid will obligated provide information that colucid reasonably determines trade secret confidential information provided lilly under this section nbsp shall considered confidential information colucid right obligation under this section nbsp will terminate upon first occur following nbsp colucid initial registered public offering nbsp colucid becomes reporting company under united state security exchange amended nbsp colucid subject change control nbsp lilly longer hold share style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center indemnification style margin margin bottom text indent font size font family time roman indemnification style margin margin bottom margin left text indent font size font family time roman colucid obligation except extent such damage negligence gross negligence willful misconduct lilly affiliate their officer director employee agent colucid shall defend indemnify hold harmless lilly affiliate their officer director employee agent against damage incurred them resulting from arising style margin margin bottom margin left text indent font size font family time roman material breach representation warranty made colucid this agreement style margin margin bottom margin left text indent font size font family time roman handling possession development manufacturing marketing distribution promotion sale product colucid permitted seller style margin margin bottom margin left text indent font size font family time roman exercise right under licensed patent lilly know colucid affiliate permitted seller permitted sublicensees style margin margin bottom margin left text indent font size font family time roman colucid failure comply material respect with applicable connection with performance obligation hereunder style margin margin bottom margin left text indent font size font family time roman other activity conducted colucid affiliate permitted seller permitted sublicensee with respect compound conducted after closing date style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left text indent font size font family time roman lilly obligation except extent such damage negligence gross negligence willful misconduct colucid affiliate their officer director employee agent lilly shall defend indemnify hold harmless colucid affiliate their officer director employee agent against damage incurred them resulting from arising style margin margin bottom margin left text indent font size font family time roman material breach representation warranty made lilly this agreement style margin margin bottom margin left text indent font size font family time roman activity conducted behalf lilly with respect right reserved under section style margin margin bottom margin left text indent font size font family time roman exercise right under colucid technology lilly affiliate pursuant section nbsp style margin margin bottom margin left text indent font size font family time roman exercise lilly right under licensed patent lilly know prior closing date style margin margin bottom margin left text indent font size font family time roman handling possession development manufacture compound prior closing date style margin margin bottom text indent font size font family time roman notice opportunity defend style margin margin bottom margin left text indent font size font family time roman notice promptly after receipt party hereto notice claim which could give rise right indemnification pursuant section nbsp such party indemnitee will give other party indemnifying party written notice describing claim reasonable detail failure indemnitee give notice manner provided herein will relieve indemnifying party obligation under this article except extent that such failure give notice materially prejudice indemnifying party ability defend such claim style margin margin bottom margin left text indent font size font family time roman defense action case action that subject indemnification under this article shall brought against indemnitee shall give written notice indemnifying party commencement thereof indemnifying party shall entitled participate desire assume defense with counsel reasonably satisfactory such indemnitee after notice from indemnifying party indemnitee election assume defense indemnifying party shall liable such indemnitee under this article other counsel other expense each case subsequently incurred such indemnitee connection with defense style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left text indent font size font family time roman indemnitee separate counsel notwithstanding foregoing indemnitee shall have right employ separate counsel participate defense such action indemnifying party shall bear reasonable cost expense such separate counsel nbsp counsel chosen indemnifying party represent indemnitee would present such counsel with conflict interest indemnifying party elect engage counsel without such conflict nbsp indemnifying party shall have employed counsel reasonably satisfactory indemnitee represent indemnitee within reasonable time after notice institution such action nbsp indemnifying party shall authorize indemnitee writing employ separate counsel indemnifying party expense style margin margin bottom margin left text indent font size font family time roman settlement indemnifying party assumes defense such action compromise settlement thereof effected indemnifying party without indemnitee written consent which consent shall unreasonably withheld delayed unless there finding admission violation violation right indemnitee effect other claim that made against indemnitee event indemnitee indemnifying party participate their expense defense such asserted claim style margin margin bottom margin left text indent font size font family time roman conduct defense notwithstanding anything contrary this section nbsp party conducting defense claim will nbsp keep other party informed reasonable timely basis status defense such claim only extent such other party participating jointly defense such claim nbsp conduct defense such claim prudent manner style margin margin bottom text indent font size font family time roman survival provision this article will survive termination expiration this agreement each indemnified party right under this article will deemed have been waived otherwise affected such indemnified party waiver breach representation warranty agreement covenant contained made pursuant this agreement unless such waiver expressly writing also waif indemnified party right under this article style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center term termination style margin margin bottom text indent font size font family time roman term term this agreement will begin upon original effective date unless sooner terminated under this article nbsp will continue full force effect country country basis territory until colucid permitted seller have remaining royalty payment obligation specific country under section nbsp upon expiration given country colucid will have fully paid style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman perpetual irrevocable license under lilly know such country closing next financing therefore closing date shall have occurred within sixty nbsp after original effective date then lilly deliver colucid notice referring this section nbsp requesting that closing next financing closing date occur such closing occur within fifteen nbsp business after colucid receipt such notice then this agreement shall automatically terminate style margin margin bottom text indent font size font family time roman material breach colucid upon material breach this agreement colucid lilly option terminate this agreement upon ninety nbsp written notice colucid such termination shall become effective such ninety nbsp period unless colucid cure such breach violation during such ninety nbsp period provided however case breach violation that cured within such ninety nbsp period lilly terminate this agreement following such ninety nbsp period only colucid shall have failed commence substantial remedial action within such ninety nbsp period best effort pursue same sake clarity colucid failure diligently develop diligently commercialize product accordance with this agreement shall deemed material breach style margin margin bottom text indent font size font family time roman notwithstanding foregoing extent material breach material default this agreement colucid affect colucid performance lilly right under this agreement relates more country country lilly terminate this agreement accordance with this section nbsp affected country country only such case this agreement will remain full force effect with respect country that terminated provided however that such default relates lilly terminate this agreement country style margin margin bottom text indent font size font family time roman right upon termination lilly lilly terminates this agreement under section nbsp colucid terminates this agreement under section nbsp then following will take effect upon effective date such termination style margin margin bottom margin left text indent font size font family time roman reversion licensed patent lilly know direct license sublicensees right under licensed patent lilly know granted lilly colucid pursuant article will terminate right granted therein will immediately revert lilly with further notice action required lilly behalf provided however that termination relates only specific country then only license pertaining such country will revert lilly hereunder sublicensee under right granted colucid hereunder which breached material respect sublicense shall entitled receive license directly from lilly granting right substantially same those granted each sublicense containing obligation licensee similar those forth this agreement provided however that nbsp each sublicensee shall expressly agree writing bound term condition such direct license nbsp obligation lilly under such direct license shall greater than obligation lilly hereunder style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left text indent font size font family time roman reversion patent maintenance responsibility upon effective date termination this agreement sole responsibility preparing filing prosecuting maintaining licensed patent will revert back lilly with further notice action required lilly behalf provided however that termination relates only specific country then only patent maintenance obligation pertaining such country will revert lilly hereunder such case colucid will maintain patent responsibility other licensed patent style margin margin bottom margin left text indent font size font family time roman exclusive license access colucid technology colucid will automatically grant lilly exclusive world wide license with right sublicense under colucid technology make have made offer sell sell import product solely country country which colucid right product were terminated party shall negotiate good faith reasonable compensation from lilly colucid such license lilly shall have right obligation expense take legal action against third person infringement colucid technology licensed under this section nbsp colucid consent party cooperate with lilly such action brought lilly pursuant this section nbsp lilly will reimburse colucid documented reasonable expense incurred colucid connection with such cooperation further settlement consent judgment other final disposition action infringement validity entered into colucid technology licensed under this section nbsp without lilly written consent which consent shall unreasonably withheld unless there finding admission either infringement validity patent under such colucid technology style margin margin bottom margin left text indent font size font family time roman disposition inventory upon termination colucid shall promptly transfer quantity remaining compound supplied lilly colucid lilly terminates this agreement after colucid obtained regulatory approval product colucid will promptly offer sell lilly designee colucid actual cost determined accordance with gaap plus reasonable markup comparable markup charged contract manufacturer pharmaceutical manufacturing industry colucid inventory product existing date termination colucid inventory colucid will entitled finish manufacturing work process into product such newly made product will considered colucid inventory hereunder lilly request colucid shall commercially reasonable style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman effort continue manufacturing lilly period time reasonably sufficient permit lilly locate qualify alternative source supply colucid then utilizing third party manufacturer colucid will commercially reasonable effort cause such supplier provide supply lilly termination this agreement relates only specific country provision this section nbsp applicable only colucid product inventory country determined colucid record where such termination occurred provided however that colucid option promptly ship inventory product such country country which retains right market sell such product style margin margin bottom margin left text indent font size font family time roman transfer regulatory document colucid shall immediately transfer possession ownership shall cause contractor used colucid provide service hereunder transfer possession ownership lilly lilly name where appropriate clinical trial data information clinical trial database data generated support application marketing authorization regulatory approval other regulatory commitment toxicology stability data regulatory document including limited application marketing authorization regulatory approval correspondence between colucid sublicensee contractor colucid regulatory agency that were created developed under term this agreement compound product collectively regulatory document provided however that termination relates only specific country then only regulatory document pertaining such country will transferred lilly hereunder such case colucid will maintain possession ownership other regulatory document should lilly elect sublicense market font style white space nowrap promote font product with third person territory pursuant lilly right under this section nbsp lilly shall have right provide appropriate access such clinical trial data information clinical trial database data generated support application marketing authorization regulatory approval other regulatory commitment regulatory document such third person except contemplated subsection nbsp above colucid shall entitled compensation regulatory material style margin margin bottom margin left text indent font size font family time roman assignment trademark colucid shall assign lilly trademark right product including without limitation back mark registration application such mark goodwill associated with such mark provided however that termination relates only specific country then only trademark right pertaining such country will transferred lilly hereunder such case colucid will maintain possession ownership other trademark party shall negotiate good faith reasonable compensation from lilly colucid such trademark goodwill style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman termination colucid style margin margin bottom margin left text indent font size font family time roman colucid reasonably belief light factor identified definition diligence article that would commercially unreasonable continue develop product forth this agreement terminate this agreement upon ninety nbsp written notice lilly style margin margin bottom margin left text indent font size font family time roman upon material breach this agreement lilly colucid option terminate this agreement upon ninety nbsp written notice lilly such termination shall become effective such ninety nbsp period unless lilly cure such breach violation during such ninety nbsp period provided however case breach violation that cured within such ninety nbsp period colucid terminate this agreement following such ninety nbsp period only lilly shall have failed commence substantial remedial action within such ninety nbsp period best effort pursue same style margin margin bottom margin left text indent font size font family time roman colucid terminates this agreement under section nbsp then term section nbsp shall apply colucid terminates this agreement under section nbsp then colucid shall retain license granted lilly pursuant section nbsp unless otherwise terminated pursuant term this agreement colucid payment obligation under article other relevant provision shall continue full force effect colucid diligence obligation under section will terminate style margin margin bottom text indent font size font family time roman termination bankruptcy notwithstanding other provision this article either party terminate this agreement providing written notice other party with immediate effect other party style margin margin bottom margin left text indent font size font family time roman make general assignment substantially asset benefit creditor style margin margin bottom margin left text indent font size font family time roman petition acquiesces appointment receiver trustee similar officer liquidate conserve business substantially asset style margin margin bottom margin left text indent font size font family time roman voluntarily commences under jurisdiction proceeding relief under bankruptcy code amended code similar bankruptcy applicable jurisdiction involving insolvency reorganization adjustment debt dissolution liquidation other similar proceeding release financially distressed debtor style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman change colucid ownership colucid undergoes change control colucid will promptly notify lilly writing thereof lilly terminate this agreement providing written notice colucid such termination shall become effective upon colucid receipt such notice unless controlling third person agrees writing bound term condition this agreement undertake colucid obligation under this agreement style margin margin bottom text indent font size font family time roman residual obligation upon termination termination this agreement reason will relieve either party obligation liability accruing prior thereto will without prejudice right remedy either party with respect antecedent breach provision this agreement without limiting generality foregoing addition foregoing right upon termination forth section nbsp termination this agreement whether lapse time otherwise will serve terminate right obligation party hereto with respect this agreement relates jurisdiction which this agreement been terminated provision article section nbsp article section article article section nbsp article intended shall survive termination expiration this agreement accordance with term such article section style margin margin bottom text indent font size font family time roman additional remedy remedy forth this article elsewhere this agreement will addition will exclusion other remedy available party equity under this agreement style margin margin bottom text indent font size font family time roman further assurance colucid covenant agrees that this agreement terminated under section nbsp regulatory document described section nbsp trademark described section nbsp transferred assigned under applicable untransferable nature then colucid will cause beneficial interest same event lilly colucid covenant agrees after such termination hold such regulatory document trademark trust benefit lilly provided payment owed colucid under this agreement have been paid lilly style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center article style margin margin bottom font size font family time roman align center miscellaneous style margin margin bottom text indent font size font family time roman independent contractor understood agreed that party shall have status independent contractor under this agreement that nothing this agreement shall construed creating partnership joint venture employer employee relationship between party authorization either colucid lilly agent other style margin margin bottom text indent font size font family time roman benefit others representation warranty covenant agreement contained this agreement sole benefit party their legal representative successor assigns they shall construed conferring right third person style margin margin bottom text indent font size font family time roman force majeure either party affected extraordinary unexpected unavoidable event such flood fire riot labor disturbance failure source supply infectious disease animal reason order proclamation regulation ordinance demand requirement relevant government authority representative thereof reason other cause whatsoever provided that such case party claiming relief account such event demonstrate that such event extraordinary unexpected unavoidable exercise reasonable care force majeure shall notify other party within five nbsp business nature extent thereof take reasonable step overcome force majeure minimize loss occasioned that other party such notice will provided within five nbsp business occurrence such event will identify requirement this agreement such obligation affected subject provision below extent affected said obligation will suspended during period such disability party prevented from performing hereunder will reasonable effort remove such disability will continue performance whenever such cause removed party affected will give other party good faith estimate continuing effect force majeure condition duration affected party nonperformance style margin margin bottom text indent font size font family time roman period previous actual nonperformance lilly because lilly force majeure condition plus anticipated future period lilly nonperformance because such condition will exceed aggregate hundred eighty nbsp consecutive within year period colucid terminate this agreement immediately written notice lilly style margin margin bottom text indent font size font family time roman period previous actual nonperformance colucid because colucid force majeure condition will exceed hundred eighty nbsp consecutive lilly terminate this agreement immediately written notice colucid provided however that extent such nonperformance colucid affect colucid style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman performance lilly right under this agreement relates more country country lilly terminate this agreement after such hundred eighty nbsp period affected country country only such case this agreement will remain full force effect with respect country that terminated style margin margin bottom text indent font size font family time roman notwithstanding foregoing when such circumstance those contemplated herein arise party will discus good faith what modification term forth herein required order arrive equitable solution style margin margin bottom text indent font size font family time roman amendment this agreement amended supplemented otherwise modified except instrument writing signed authorized representative party style margin margin bottom text indent font size font family time roman entire agreement this agreement constitutes entire agreement understanding relating subject matter this agreement supersedes previous communication proposal representation agreement whether oral written relating subject matter this agreement including confidentiality font style white space nowrap font agreement dated september nbsp original agreement prior amendment style margin margin bottom text indent font size font family time roman severability provision this agreement held illegal invalid unenforceable under present future effective while this agreement remains effect legality validity enforceability remaining provision will affected thereby style margin margin bottom text indent font size font family time roman waiver term provision this agreement waived time party entitled benefit thereof only written instrument executed such party delay part lilly colucid exercising right power privilege hereunder will operate waiver thereof will waiver part either lilly colucid right power privilege hereunder operate waiver other right power privilege hereunder will single partial exercise right power privilege hereunder preclude other further exercise thereof exercise other right power privilege hereunder style margin margin bottom text indent font size font family time roman notice notice required permitted given under this agreement shall writing shall deemed given upon receipt delivered personally facsimile transmission receipt verified telexed mailed registered certified mail return receipt requested postage prepaid sent prepaid express courier service party following address such other address party shall specified notice provided that notice change address shall effective only upon receipt thereof style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center align right table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width style font family time roman font size valign nbsp colucid valign bottom valign colucid pharmaceutical style font family time roman font size valign valign bottom valign style font family time roman font size valign valign bottom valign cambridge massachusetts style font family time roman font size valign valign bottom valign attention chief executive officer style font size height height colspan style font family time roman font size valign with nbsp nbsp copy nbsp valign bottom valign style font size margin margin bottom nbsp style margin margin bottom font size font family time roman faegre baker daniel style margin margin bottom font size font family time roman east style font size vertical align suite style margin margin bottom font size font family time roman indianapolis indiana style margin margin bottom font size font family time roman attention daniel boeglin style margin margin bottom font size font family time roman font style white space nowrap font style font size height height colspan style font family time roman font size valign lilly valign bottom valign style margin margin bottom font size font family time roman lilly company style margin margin bottom font size font family time roman lilly corporate center style margin margin bottom font size font family time roman indianapolis indiana style margin margin bottom font size font family time roman united state america style margin margin bottom font size font family time roman attention general counsel style margin margin bottom font size font family time roman font style white space nowrap font style font size height height colspan style font family time roman font size valign with copy valign bottom valign style font size margin margin bottom nbsp style margin margin bottom font size font family time roman lilly company style margin margin bottom font size font family time roman lilly corporate center style margin margin bottom font size font family time roman indianapolis indiana style margin margin bottom font size font family time roman united state america style margin margin bottom font size font family time roman attention vice president neuroscience table style margin margin bottom text indent font size font family time roman governing this agreement shall governed construed accordance with state indiana united state excluding choice rule which direct application other jurisdiction however scope validity enforceability patent encompassed within scope this agreement shall determined accordance with applicable country which such patent have issued style margin margin bottom text indent font size font family time roman assignability during term this agreement neither party shall assign benefit burden under this agreement without prior written consent other party which shall unreasonably withheld except that nbsp either party assign right obligation under this agreement affiliate company with which merge consolidate company whom transfer substantially asset company which acquire such party including each case company created vehicle upon such merger transfer acquisition nbsp colucid transfer right sublicensee provided this agreement nbsp lilly freely assign royalty interest whole part this agreement shall binding inure benefit party hereto their respective permitted successor assigns style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman jointly prepared this agreement will deemed have been drafted both lilly colucid will construed against either party draftsperson hereof style margin margin bottom text indent font size font family time roman heading gender number section article title caption contained this agreement exhibit schedule certificate referred herein annexed this agreement convenience only will deemed part this agreement will affect meaning interpretation this agreement word used herein regardless number gender specifically used shall deemed construed include other number singular plural other gender masculine feminine neuter context requires style margin margin bottom text indent font size font family time roman dispute resolution dispute arises relating this agreement prior instituting lawsuit other dispute resolution process account such dispute party will attempt good faith settle such dispute first negotiation consultation between themselves including referral such dispute chief executive officer colucid vice president neuroscience lilly such executive unable resolve such dispute agree upon mechanism resolve such dispute within sixty nbsp first written request dispute resolution under this section nbsp then request either party dispute shall submitted binding mediation before mutually acceptable mediator chosen agreement party this provision shall preclude party from seeking immediate injunctive relief event such party belief that irreparable harm will occur style margin margin bottom text indent font size font family time roman counterpart this agreement executed more counterpart each which shall original which taken together shall constitute same agreement shall necessary making proof this agreement counterpart hereof produce account other counterpart style margin margin bottom text indent font size font family time roman schedule exhibit attachment schedule exhibit attachment including without limitation development plan referred herein intended hereby specifically made part this agreement however there conflict between term condition such schedule exhibit attachment this agreement term condition this agreement shall prevail style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman further assurance time during term this agreement lilly colucid each will request other party reasonable effort nbsp deliver other party such record data other document consistent with provision this agreement nbsp execute deliver cause delivered such assignment consent document further instrument transfer license nbsp take cause taken such other action party reasonably deem necessary desirable order such party obtain full benefit this agreement transaction contemplated hereby style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom text indent font size font family time roman small small small itness small small hereof small party their respective authorized representative have executed this agreement style font size margin margin bottom nbsp align right table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width style font family time roman font size valign colspan small small small illy small small small small ompany small style font size height height colspan style font family time roman font size valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman darren carroll style font family time roman font size valign printed valign bottom valign darren carroll style font family time roman font size valign title valign bottom valign corporate style font size height colspan style font family time roman font size valign colspan small small small ucid small small harmaceuticals small small small style font size height height colspan style font family time roman font size valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman thomas mathers style font family time roman font size valign printed valign bottom valign thomas mathers style font family time roman font size valign title valign bottom valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center licensed patent style margin margin bottom font size font family time roman style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width valign bottom width width valign bottom width width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman docket nbsp valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center country valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center status valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center substatus valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center application nbsp number valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center nbsp date valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center patent nbsp number valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center grant nbsp date valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center expiration nbsp date style font family time roman font size valign valign bottom nbsp valign algeria valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign argentina valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign australia valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign brazil valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign canada valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign chile valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign china valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign colombia valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign costa rica valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign croatia valign bottom nbsp valign filed valign bottom nbsp valign published valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign ecuador valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign salvador valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign eurasian patent convention valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign european patent convention valign bottom nbsp valign filed valign bottom nbsp valign published valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign hong kong valign bottom nbsp valign docketed valign bottom nbsp valign mailed valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign indonesia valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign israel valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign japan valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign korea south valign bottom nbsp valign filed valign bottom nbsp valign published valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign malaysia valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign mexico valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign zealand valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign nigeria valign bottom nbsp valign granted valign bottom nbsp valign granted valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign align right style font family time roman font size valign valign bottom nbsp valign norway valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign patent cooperation treaty valign bottom nbsp valign inactive valign bottom nbsp valign national valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign peru valign bottom nbsp valign filed valign bottom nbsp valign published valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign philippine valign bottom nbsp valign filed valign bottom nbsp valign published valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign poland valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign singapore valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign south africa valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign taiwan valign bottom nbsp valign filed valign bottom nbsp valign published valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign thailand valign bottom nbsp valign filed valign bottom nbsp valign published valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign ukraine valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign united state valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign venezuela valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign vietnam valign bottom nbsp valign inactive valign bottom nbsp valign abandoned valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign egypt valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign india valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign style font family time roman font size valign valign bottom nbsp valign pakistan valign bottom nbsp valign filed valign bottom nbsp valign filed valign bottom nbsp valign valign bottom nbsp valign align right valign bottom nbsp valign valign bottom nbsp valign valign bottom nbsp valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center compound supply style margin margin bottom font size font family time roman style margin margin bottom margin left font size font family time roman transferred colucid shall solely responsible determining suitability developmental clinical trial style margin margin bottom margin left font size font family time roman hemisuccinate manufactured located belgium style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign material past evaluation date table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign material event used pivotal clinical trial table style margin margin bottom margin left font size font family time roman additional available that suitable development only shall circumstance used human style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign reference standard available will need evaluation colucid before this material made using cgmp table style margin margin bottom font size font family time roman analytical method style margin margin bottom margin left font size font family time roman analytical method have been developed will supplied transferred validation will required colucid analytical prior style margin margin bottom font size font family time roman drug product style margin margin bottom margin left font size font family time roman drug product transferred colucid shall solely responsible determining suitability developmental clinical trial style margin margin bottom margin left font size font family time roman unlabeled vial material available style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign material past expiry dating table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign stability sample that useful extend dating still stability chamber party will remain until table style margin margin bottom margin left font size font family time roman since material imported import export shipment material need comply with style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman near term migraine product development plan style margin margin bottom font size font family time roman product assumption style margin margin bottom font size font family time roman triptan similar efficacy need prove absence human coronary vasoconstriction with comparison triptan marketing style margin margin bottom font size font family time roman potential efficacy prophylactic migraine drug preventive agent given onset aura during prodrome this will part this proposed development plan style margin margin bottom font size font family time roman need demonstrate that nausea vomiting phonophobia photophobia improved considers pain improvement absence improvement other feature inadequate style margin margin bottom font size font family time roman administered sublingual oral style margin margin bottom font size font family time roman might have efficacy delayed emesis style margin margin bottom font size font family time roman development plan style margin margin bottom font size font family time roman migraine style margin margin bottom font size font family time roman phase study agent shown table given thorough toxicology package that been performed molecule thought that extensive additional study will need performed prior phase study with sublingual formulation preparation formulation will require animal study demonstrate lack irritability administration absorption drug substance preparation study drug included cost estimate phase study could potentially compare sublingual formulation oral assuming data from study clean phase could proceed there possibility that additional study will required examine cardiac issue marketing reason these might helpful style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman phase study acute migraine moderate severe shown table phase study would include initial study determine maximum tolerated dose second study would proof concept study multiple dose study also planned style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman delayed emesis style margin margin bottom font size font family time roman since delayed emesis will submitted different division likely that that division would request full exposure that indication this could discussed smaller exposure might negotiated style margin margin bottom font size font family time roman phase study delayed emesis shown table style margin margin bottom font size font family time roman fastest route efficacy study migraine style margin margin bottom font size font family time roman given that animal have been dosed regulatory week intravenous study defining noael dose that intravenous study been done subject defining that dosage form planned sublingual oral first clinical pharmacology study will single dose escalation find maximal tolerated dose there would minimum group subject each dosed dosage level kinetics sublingual dosing should compared dosing study progress help define maximal tolerated dose will notice table below that there additional study which would likely beneficial clinical trial multiple dosing multiple dose clinical pharmacology trial will required demonstrate pharmacokinetics safety steady state style margin margin bottom font size font family time roman clinical study would moderate severe acute migraine which will single dose patient meet study criterion given blinded study drug take with their next moderate severe migraine headache they subsequently complete diary recording severity their symptom defined time over next several hour this study would study drug maximum tolerated dose placebo efficacy this trial would sufficient move forward style margin margin bottom font size font family time roman fastest route efficacy study delayed emesis style margin margin bottom font size font family time roman this study will require toxicology support least week addition single dose preclinical pharmacology trial clinical pharmacology study subject dosed maximum tolerated efficacy dose steady state will needed efficacy study requiring week dosing should sufficient proof concept trial style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman table projected clinical phase plan registration style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman study objective valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center design valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center duration valign bottom nbsp nbsp valign bottom align center style border bottom solid style font family time roman font size valign absolute bioavailability valign bottom nbsp nbsp valign crossover versus sublingual oral kinetics valign bottom nbsp nbsp valign single dose valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign multiple dose valign bottom nbsp nbsp valign parallel include evaluation steady state kinetics valign bottom nbsp nbsp valign week valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp nbsp valign study could potentially combined into multiple dose study looking kinetics valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign subtotal valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign drug nbsp interaction nbsp study nbsp several these depending upon characteristic drug valign bottom nbsp nbsp valign crossover these would include analgesic prophylaxis agent chemotherapeutic agent that will used concomitantly with this formulation valign bottom nbsp nbsp valign single dose valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp nbsp valign this study drug interaction will likely have performed valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign subtotal valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign trial migraineurs valign bottom nbsp nbsp valign cross over dose response efficacy valign bottom nbsp nbsp valign multiple single valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign cardiac catheterization constriction absence valign bottom nbsp nbsp valign parallel dose response placebo controlled include this should only performed after consultation with ability differentiating label valign bottom nbsp nbsp valign single dose valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp nbsp valign these study required depending cardiac evaluation look first study above based phase conducted clean study this should case valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman table phase clinical plan migraine style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman phase indication valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center study objective valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center design valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center duration valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center number nbsp patient style font family time roman font size valign phase moderate severe migraine pain valign bottom nbsp nbsp valign dose response efficacy study safety valign bottom nbsp nbsp valign parallel placebo controlled include evaluation valign bottom nbsp nbsp valign single migraine consider follow data confirm safety valign bottom nbsp nbsp valign nbsp nbsp nbsp nbsp style font size height height colspan height colspan height colspan height colspan style font family time roman font size valign phase moderate severe migraine pain valign bottom nbsp nbsp valign dose response efficacy study best dose from study other safety valign bottom nbsp nbsp valign parallel placebo controlled include evaluation valign bottom nbsp nbsp valign single migraine consider follow data confirm safety valign bottom nbsp nbsp valign style font size height height colspan height colspan height colspan height colspan style font family time roman font size valign phase repeated dose migraine study valign bottom nbsp nbsp valign efficacy safety valign bottom nbsp nbsp valign parallel comparator placebo controlled consider imbalance second dose nonresponders valign bottom nbsp nbsp valign style margin margin bottom font size font family time roman single style margin margin bottom font size font family time roman alternatively could treat migraine valign bottom nbsp nbsp valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman table phase study delayed emesis indication submission without migraine package style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman phase indication valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center study objective valign bottom nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center design valign bottom nbsp valign bottom align center style border bottom solid duration valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center number nbsp style margin margin bottom font size font family time roman align center patient style font family time roman font size valign phase proof concept valign bottom nbsp valign stand alone valign bottom nbsp valign parallel placebo valign bottom nbsp valign nowrap font style white space nowrap nbsp week font valign bottom nbsp nbsp valign nbsp nbsp nbsp nbsp style font size height height colspan height colspan height colspan height colspan style font family time roman font size valign phase proof concept valign bottom nbsp valign nbsp nbsp standard nbsp therapy valign bottom nbsp valign parallel placebo valign bottom nbsp valign nbsp week valign bottom nbsp nbsp valign nbsp nbsp style font size height height colspan height colspan height colspan height colspan style font family time roman font size valign phase dose response valign bottom nbsp valign efficacy valign bottom nbsp valign parallel placebo valign bottom nbsp valign nbsp week valign bottom nbsp nbsp valign nbsp nbsp nbsp nbsp style font size height height colspan height colspan height colspan height colspan style font family time roman font size valign phase dose response valign bottom nbsp valign style margin margin bottom font size font family time roman efficacy nbsp nbsp style margin margin bottom font size font family time roman standard nbsp therapy valign bottom nbsp valign parallel placebo valign bottom nbsp valign nbsp week valign bottom nbsp nbsp valign nbsp nbsp table style margin margin bottom font size font family time roman this plan assumes that dosage will similar that migraine that will accept safety data migraine permit reduced number exposure style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center know style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap align center style border bottom solid width font size font family time roman align center adme valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme summary slide valign bottom nbsp nbsp valign align center adme summary slide style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center valign bottom nbsp nbsp valign align center elimination radioactivity from female beagle following either single intravenous dose single oral dose hemisuccinate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center valign bottom nbsp nbsp valign align center file name style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center plasma pharmacokinetics radioactivity blood cell distribution female beagle following single intravenous oral dose hemisuccinate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center synthesis trifluoro methyl piperidinyl carbonyl pyridinyl benzamide hemisuccinate hemisuccinate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme metab valign bottom nbsp nbsp valign align center metabolism female beagle following nbsp single intravenous single oral dose middot hemisuccinate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center vitro metabolism studied liver microsome cryopreserved hepatocytes from human monkey vivo metabolism studied plasma from monkey urine from style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center plasma toxicokinetics fischer following intravenous infusion nbsp hemisuccinate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center toxicokinetics beagle following single intravenous infusion hemisuccinate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center drug effect hepatic microsomal drug metabolizing enzyme beagle given hemisuccinate intravenous infusion week style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center toxicokinetics gravid zealand white rabbit following single intravenous infusion hemisuccinate gestation style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center toxicokinetics gravid zealand white rabbit following single intravenous infusion hemisuccinate gestation style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign align center adme valign bottom nbsp nbsp valign align center plasma toxicokinetics gravid gestation following daily intravenous infusion hemisuccinate salt gestation through table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center valign bottom width width valign bottom width width style font size height height colspan height colspan style font family time roman font size valign align center valign bottom valign align center adme valign bottom valign align center vitro interaction with human cytochrome style font size height height colspan height colspan style font family time roman font size valign align center valign bottom valign align center adme valign bottom valign align center synthesis trifluoro methyl piperidinyl carbonyl pyridinyl benzamide hemisuccinate hemisuccinate table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap align center style margin margin bottom font size font family time roman align center style margin margin bottom border bottom solid width font size font family time roman align center toxicology valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center file name valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center document title style font family time roman font size valign align center valign bottom nbsp nbsp valign toxicology summary slide valign bottom nbsp nbsp valign toxicology summary slide style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign genpharm receptor valign bottom nbsp nbsp valign receptor pharmacology study difumarate using radiolabeled receptor binding isolated tissue bath preparation style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign genpharm herg valign bottom nbsp nbsp valign human cardiac herg blocking profile compound hydrochloride style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign genpharm respiratory valign bottom nbsp nbsp valign effect single dose oral administration difumarate respiratory pattern male style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign genpharm valign bottom nbsp nbsp valign behavioral effect single dose oral administration difumarate male mouse style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign genpharm valign bottom nbsp nbsp valign telemetry cardiovascular assessment study conscious orally administered compound difumarate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign genpharm hemolysis valign bottom nbsp nbsp valign hemolytic potential blood compatibility testing with hemisuccinate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign single_dose valign bottom nbsp nbsp valign single dose toxicity study fischer given hemisuccinate intravenously style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign vitro ocular valign bottom nbsp nbsp valign bovine corneal opacity permeability assay hemisuccinate compound final report style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign micronucleus valign bottom nbsp nbsp valign effect hemisuccinate given intravenously consecutive induction micronuclei bone marrow mouse style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign chrom valign bottom nbsp nbsp valign effect hemisuccinate vitro induction chromosome aberration chinese hamster ovary cell style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign ames valign bottom nbsp nbsp valign effect hemisuccinate induction reverse mutation salmonella typhimurium escherichia coli using ames test style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign repeat_dose valign bottom nbsp nbsp valign week intravenous infusion toxicity study hemisuccinate compound fischer style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign repeat_dose valign bottom nbsp nbsp valign week intravenous infusion toxicity study hemisuccinate beagle style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign embryofetal valign bottom nbsp nbsp valign embryo fetal development study hemisuccinate compound administered intravenous infusion companion blood level study style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign embryofetal rabbit valign bottom nbsp nbsp valign embryo fetal development segment study hemisuccinate compound administered intravenously zealand white rabbit table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap align center style margin margin bottom font size font family time roman align center style margin margin bottom border bottom solid width font size font family time roman align center discovery valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center file name valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center document title style font family time roman font size valign align center valign bottom nbsp nbsp valign discovery summary slide valign bottom nbsp nbsp valign discovery summary slide style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign f_candidate selection document valign bottom nbsp nbsp valign candidate selection document description preclinical work table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap align center style margin margin bottom font size font family time roman align center style margin margin bottom border bottom solid width font size font family time roman align center clinical valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center file name valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center document title style font family time roman font size valign align center valign bottom nbsp nbsp valign clinical summary slide valign bottom nbsp nbsp valign clinical summary slide style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign current style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign frlaca valign bottom nbsp nbsp valign phase clinical study laca final study report table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap align center style margin margin bottom font size font family time roman align center style margin margin bottom border bottom solid width font size font family time roman align center valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center file name valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center document title style font family time roman font size valign align center valign bottom nbsp nbsp valign summary slide valign bottom nbsp nbsp valign summary slide style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign summation analytical method report valign bottom nbsp nbsp valign summary index hard copy file style font size height height colspan height colspan style font family time roman font size valign bottom nowrap align center style border bottom solid width font size font family time roman align center analytical method valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign hplc determination toxicology formulation style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign hplc determination from texwipe swab style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign hplc determination from texwipe swab style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign validation protocol method hplc determination cleaning swab style font size height height colspan height colspan style font family time roman font size valign bottom nowrap align center style border bottom solid width font size font family time roman align center valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp style font family time roman font size valign align center valign bottom nbsp nbsp valign campaign development report valign bottom nbsp nbsp valign campaign development report style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign hemisuccinate analytical method unofficial result valign bottom nbsp nbsp valign hemisuccinate analytical method official result style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign optimisation robustness study last step valign bottom nbsp nbsp valign optimisation robustness study last step synthesis candidate style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign pilot plant campaign production report valign bottom nbsp nbsp valign pilot plant campaign production report style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign biopharmaceutical property program generation style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign biopharmaceutical property salt selection program generation style font size height height colspan height colspan style font family time roman font size valign bottom nowrap align center style border bottom solid width font size font family time roman align center formulation valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign formulation development report parenteral solution formulation first human dose study style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign formulation development report parenteral solution formulation first human dose study style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign formulation development report drug excipient compatibility study style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign prediction bitter taste using behavioral taste model style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign formulation development report prototype sublingual tablet formulation development vivo absorption style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign valign bottom nbsp nbsp valign microbial challenge testing hemisuccinate salt solution injection table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center style page break before always size style color width align center table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap align center style border bottom solid width font size font family time roman align center specification valign bottom nbsp nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom nbsp style font family time roman font size valign align center valign bottom nbsp nbsp valign spec valign bottom nbsp nbsp valign specification approval drug product style font size height height colspan height colspan style font family time roman font size valign align center valign bottom nbsp nbsp valign spec valign bottom nbsp nbsp valign specification approval drug product table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential treatment requested style margin margin bottom font size font family time roman certain confidential information contained this document marked with bracket been omitted filed separately with security exchange commission pursuant request confidential treatment pursuant applicable rule security amended rule security exchange amended style margin margin bottom font size font family time roman align center body html text document